Cefotaxime is a new cephalosporin with a spectrum of activity which may make it appropriate for use in pediatric patients. In 33 infants and children, administration of cefotaxime resulted in cure or improvement in 97% of patients, with eradication of 94% of isolated pathogens. Toxicity was minimal. The disposition of cefotaxime in this age group was similar to that reported for adults, with an elimination half-life of approximately 1.5 h, a volume of distribution of 1 liter/kg, a total serum clearance of 10 ml/min per kg, and a renal clearance of 6 ml/min per kg.
Cefotaxime (HR 756 ) is one of a number of new cephalosporins with enhanced bacterial spectra which have been developed during the last few years. This parenteral cephalosporin has remarkable activity against gram-positive and -negative aerobic and anaerobic bacteria in concentrations much lower than those required for other agents. Moreover, this compound is active against 8B-lactamase-producing Enterobacteriaceae, Haemophilus influenzae, and Neisseria spp. (3, 6, 13) . This spectrum renders the compound suitable for treating infections in pediatric patients. We decided, therefore, to study its efficacy and pharmacokinetics in infants and children (8 Cefotaxime administration. Cefotaxime alone was administered to these patients. It was supplied in sodium salt form by Hoechst Akiengesellschaft. Cefotaxime in 500-or 1,000-mg amounts in vials was diluted in 5 or 10 ml of distilled water, respectively, before injection. The drug was administered intramuscularly in 7 patients and as 1-min intermittent intravenous injections in 26. All patients received 25-mg/kg doses every 6 h. The duration of therapy ranged from 7 to 28 days. Blood was drawn by heel prick before and at 0.5, 1, 2, 3, 4, and 6 h after an intramuscular dose during the first 24 h of treatment. In patients who received the drug intravenously, an additional blood sample was obtained 5 min after injection. Urine samples were collected from 28 patients, 5 of whom received the drug intramuscularly and 23 of whom received the drug intravenously. Urine was collected immediately before injection and at 0 to 2, 2 to 4, and 4 to 6 h after cefotaxime administration. Serum and urine samples were quickly frozen and stored at -20°C until assayed (not stored longer than 2 weeks).
Efficacy and safety. The drug was administered only when the patient was diagnosed clinically and bacteriologically as suffering from a specific infection with an isolated pathogen susceptible to cefotaxime. Effectiveness was determined clinically as bacteriological eradication of pathogens and with suitable laboratory tests and X rays. All patients were carefully observed for side effects, and laboratory tests were performed before and after therapy to detect hemopoietic, hepatic, and renal toxicity.
Assay. Cefotaxime was assayed by the agar wellplate diffusion technique with DST agar (Difco Laboratories) (9) . Large plates (30 by 30 cm) were used, and standards as well as samples were set in triplicate. Standards were prepared in horse serum and phosphate buffer at pH 7.2 for the assays of serum and urine concentrations, respectively. All standards were prepared on the same day that each series of samples was obtained and were stored at -20°C until assayed. The weighting function of the fit was 1/0C,2 and the quality of fit was assured by examining residuals, visual inspection of the fit, and R-(1). Pharmacokinetic parameters for each patient were calculated with equations described by Wagner (12) (8) . It is highly active against both ampicillin-sensitive and -resistant H. influenzae, most of the Enterobacteriaceae, and some P. aeruginosa strains (3, 6, 13) .
This study of 33 seriously ill pediatric patients has shown that cefotaxime administered intravenously or intramuscularly produces blood and urine concentrations sufficient to cure or improve 97% of the patients and eradicate 94% of 
